



22nd ANNUAL INDUSTRY/ACADEMIA PRECISION ONCOLOGY & RADMED SYMPOSIUM

JUNE 11, 2026 | 8AM - 6PM | THE ALEXANDRIA AT TORREY PINES, LA JOLLA, CALIFORNIA

Agenda

8:00 **Registration and Networking Breakfast**

8:30 *Welcome Remarks*

Arno J. Mundt, MD, FACRO, FASTRO, UC San Diego

Ida Deichaite, PhD, UC San Diego

Session Title: Converging Modalities in Cancer Therapy: From Immune Activation to Precision Intervention

Time: 8:40 – 10:10

Session Chairs: Ezra Cohen, MD, Tempus; Asona Lui, MD, PhD, UC San Diego

8:45 *INBRX-106 first clinical validation of OX40 agonist induced costimulation in a randomized clinical study*
Mark Lappe, PhD, Inhibrx

8:55 *Discovery and optimization of NEO-811, a first-in-class molecular glue degrader of ARNT, utilizing structure-based drug design*
Jennifer Griffin, PhD, Neomorph

9:05 *New frontiers in immunotherapy - the development of a PD1xVEGFxIL2 trispecific immune checkpoint inhibitor*
Fredrik Wiklund, Bright Peak Therapeutics

9:15 *Longitudinal Methylation ctDNA Predicts Immunotherapy Progression Across Solid Tumors*
David Tsao, PhD, BilliontoOne

9:25 *Plants as bioreactors for next-gen immune-oncology products: from canine cancer trials to space missions*
Nicole Steinmetz, PhD, UC San Diego

9:35 *Irreversible Electroporation: Combining Tumor Ablation with Potential for Intratumoral Drug Delivery*
Rebekah White, MD, FACS, UC San Diego

9:45 Q&A and Panel Discussion

10:10 **Break**

Session Title: Targeting the RAS Pathway: Advances in KRAS and Beyond

Time: 10:25 – 11:45

Session Chairs: James Christensen, PhD, Terremoto Biosciences; Jake Haling, PhD, NewCo

10:25 *Duane Roth Achievement Award Presentation & Lecture*
Virtual Congratulatory Remarks from Rep. Scott Peters, California's 50th District, House of Representatives, United States Congress

Old Targets, New Tricks: FTIs and Menin Inhibitors as Precision Combination Agents
Recipient Troy Wilson, PhD, JD, Kura Oncology

10:55 *Targeting Oncogenic RAS with Tri-Complex RAS(ON) Inhibitors*
Elena Koltun, PhD, Revolution Medicines

11:05 *Clinical update on KRAS inhibitors in NSCLC*
Lyudmila Bazhenova, MD, UC San Diego

11:15 *Discovery and preclinical activity of macrocyclic pan-KRAS inhibitors*
Charles Cho, PhD, Novartis Biomedical Research

11:25 Q&A and Panel Discussion

11:45 **Lunch**

12:45 **Featured Talk: The Golden Years of Biotech – How Long Will They Last?**

Josh Schimmer, MD, Cantor Fitzgerald and Co.

Introduction by Hunter Reed, MBA, Alexandria Venture Investments, Alexandria Real Estate Equities, Inc.

Scan to learn about the



Duane Roth
Achievement Award



22nd ANNUAL INDUSTRY/ACADEMIA PRECISION ONCOLOGY & RADMED SYMPOSIUM

JUNE 11, 2026 | 8AM - 6PM | THE ALEXANDRIA AT TORREY PINES, LA JOLLA, CALIFORNIA

Session Title: **AI-Driven Precision Oncology: From Drug Discovery to Virtual Patients**

Time: 1:10 – 2:15

Session Chairs: Sandip Patel, MD, UC San Diego; Paul Rejto, PhD, Pfizer

- 1:15 *AI-Guided Discovery of IAM1363: A Clinical-Stage, Next-Generation HER2 Type II Inhibitor with High Selectivity and Brain Penetrance*
Laurent Gomez, PhD, Iambic Therapeutics
- 1:25 *Beyond Multiomics*
Michael Goldberg, PhD, BostonGene Corporation
- 1:35 *Building a virtual cancer patient: Multimodal AI for Precision Oncology*
Erik Bergstrom, PhD, Natara
- 1:45 *High-Dimensional, Multiplexed, and Condition-Aware Curation of Protein Interactome Datasets to Power AI*
Alon Goren, PhD, UC San Diego
- 1:55 Q&A and Panel Discussion

Session Title: **Cracking the Undruggable: From Covalent Biology to Functional Readouts**

Time: 2:15 – 3:20

Session Chairs: Laure Escoubet, PhD, Light Horse Therapeutics; J. Silvio Gutkind, PhD, UC San Diego

- 2:20 *Enlaza's War-Lock Platform: Introducing Covalency into Protein Therapeutics*
Danny Beck, Enlaza Therapeutics
- 2:30 *Discovery of PARG Inhibitor ETX-19477*
Jeffrey Stafford, PhD, 858 Therapeutics
- 2:40 *Exploiting the Achilles Heel of Historically Undruggable MYC through Small Molecule Mediated Context-Dependent Translation Inhibition*
Lawrence Hamann, PhD, Interdict Bio
- 2:50 *Fluorescent Biosensors for Oncogenic Activity Tracking and Live Cell Pharmacology*
Jin Zhang, PhD, UC San Diego
- 3:00 Q&A and Panel Discussion

3:20 **Break**

Session Title: **Radioligand Therapy in Precision Oncology: Integrating Imaging, Theranostics, and Immunotherapy**

Time: 3:35 – 4:45

Session Chairs: Christine B. Chung, MD, UC San Diego; Todd A. Pawlicki, Ph.D., FAAPM, FASTRO, UC San Diego

- 3:40 *Clinical Translation of Dosimetry-Guided Theranostics with anti-PD-1/L1 Checkpoint Inhibitors*
Evan Sengbusch, PhD, Archeus Technologies
- 3:50 *Women's Cancer Imaging*
Rebecca Rakow-Penner, MD, PhD, UC San Diego
- 4:00 *Next generation radiopharmaceuticals in advanced prostate cancer*
Zhengtao Qin, PhD, AstraZeneca
- 4:10 *RYZ-801: A Novel GPC3-Targeted Therapeutic for Hepatocellular Carcinoma*
Steven Horton, PhD, RayzeBio, a Bristol Myers Squibb Company
- 4:20 *The landscape of opportunities for combining theranostics and radiotherapy in prostate cancer*
Tyler Seibert, MD, PhD, UC San Diego
- 4:30 Q&A and Panel Discussion
- 4:45 *Fireside Chat*
Moderator: Laura Shawver, PhD
John Reed, MD, PhD, Johnson & Johnson
- 5:15 *Closing Remarks*
Andrew Sharabi, MD, PhD, UC San Diego
- 5:20 **Networking Reception**